Palisade Bio, Inc.
PALIHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Palisade Bio, Inc. (PALI) is listed under Biotechnology. Valued at $383.4M, PALI is a small-cap name in its sector. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Market Cap
$383.4M
Beta
1.55
P/E (TTM)
3.38
P/E (Fwd)
-7.86
EPS (TTM)
$0.65
EPS (Fwd)
$-0.28
ROE
-51.4%
ROA
-33.0%
Cash
$125.2M
Total Debt
$0
Free CF
-$8.7M
52W Change
273.2%
Annual Financials
Cash vs Debt
Where PALI stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, PALI finished 1.04% above its 150-day moving average ($1.93) and 0.52% above its 200-day moving average ($1.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PALI overbought or oversold?
At the September 1, 2026 close, PALI's RSI(14) was 41.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Palisade Bio, Inc. reports $125.2M in cash and $0 in total debt. Free cash flow is running at -$8.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -51.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Palisade Bio, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Palisade Bio, Inc.'s trajectory.